RT Journal Article
SR Electronic
T1 Exertional dyspnea relief following bronchodilation in COPD: Role of neural respiratory drive
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4626
DO 10.1183/13993003.congress-2015.PA4626
VO 46
IS suppl 59
A1 Courtney Wilkinson-Maitland
A1 Benoit Borel
A1 Helene Perrault
A1 Alan Hamilton
A1 Jean Bourbeau
A1 Francois Maltais
A1 Dennis Jensen
YR 2015
UL http://erj.ersjournals.com/content/46/suppl_59/PA4626.abstract
AB We hypothesized that exertional dyspnea relief following acute bronchodilation in COPD reflects the awareness of reduced neural respiratory drive. In a randomized double-blind crossover study, 20 patients (13 men) aged 68.0±1.5 yrs (mean±SE) with GOLD stage II-IV COPD (FEV1=50±3% predicted) performed four 3-min stair stepping tests at 14, 16, 20 and 24 steps/min (externally paced) after inhalation of nebulized placebo or Combivent® (500 µg ipratropium bromide/2.5 mg salbutamol). Assessments of dyspnea, ventilation (VE), breathing pattern, dynamic operating lung volumes, crural diaphragm EMG activity (EMGdi; an index measure of neural respiratory drive), and transdiaphragmatic pressure swings (Pdi,swing) were compared between treatments at each step rate. Compared to placebo, Combivent®improved dyspnea, breathing pattern, inspiratory capacity, inspiratory reserve volume (IRV), EMGdi and Pdi,swing at any given step rate and VE during exercise. By contrast, the relationship between exercise-induced changes in 1) EMGdi and Pdi,swing and 2) each of dyspnea, IRV and EMGdi were relatively preserved during exercise following treatment with Combivent® vs. placebo. Exertional dyspnea relief following bronchodilation in COPD can be largely explained by the awareness of reduced neural respiratory drive (EMGdi) needed to achieve a given VE in the setting of more favorable dynamic operating lung volumes.